ck1δ

D4476 (Casein Kinase I Inhibitor) is an effective, selective, and cell-permeant CK1 (casein kinase 1) inhibitor( IC50=300 nM in a cell-free assay).

Casein Kinase inhibitor A51 is an orally active casein kinase 1α (CK1α) inhibitor with anticancer activity that induces apoptosis in leukemia cells, and may be used in the study of neck cancers, acute myeloid leukemia, breast and prostate cancers.

Casein kinase 1δ-IN-1 (WAY-643895) is an inhibitor of casein kinase 1δ (CK1δ) and can be utilized in the study of neurodegenerative diseases, such as Alzheimer's disease.

PF-5006739 is a potent and selective CK1δ/ε inhibitor with IC50 values of 3.9 nM and 17.0 nM, respectively.It can be used in the study of psychiatric disorders and exhibits low nanomolar in vitro potency against CK1δ/ε and high kinome selectivity.PF-5006739 dose-dependently reduces opioid-seeking behavior in rodent relapse models and improves glucose tolerance in mouse models of diet-induced obesity (DIO) and genetic obesity (ob/ob).

LY-364947 (HTS466284) is a potent ATP-competitive inhibitor of TGFβR-I.

SR-3029 is a highly potent and specific inhibitor of CK1δ/CK1ε.

TA-01 is a potent inhibitor of CK1 and p38 MAPK, with IC50 values of 6.4 nM for CK1ε, 6.8 nM for CK1δ, and 6.7 nM for p38 MAPK.

Casein kinase 1δ-IN-3 (Compound 23a) is an inhibitor of casein kinase 1 delta (CK1δ) with a pIC50 of 6.5376 M.

Casein kinase 1δ-IN-6 is a potent and selective inhibitor of the protein kinase CK-1δ with an IC50 of 23 nM, demonstrating neuroprotective and anti-inflammatory activity in both in vitro and in vivo assays. Casein kinase 1δ-IN-6 can be used to study neurodegenerative diseases.

CK1-IN-2 (compound Nr.4) is a potent CK1 inhibitor with IC50 values of 123, 19.8, 26.8, and 74.3 nM for CK1a, CK1d, CK1e, and p38a, respectively, and is used in DUX4 overexpression-associated diseases, such as muscular dystrophy.

CK1δ-IN-3 (compound 376) is a CK1δ (casein kinase 1δ) inhibitor that can be used to study neurodegenerative diseases such as Alzheimer's disease.

CK1δ-IN-6 (Compound 303) is an inhibitor of Casein kinase 1δ, with potential applications in Alzheimer's disease research.

CK1δ/CK1ε ligand-1 is a ligand of CK1δ/CK1ε and can serve as a target protein ligand for the synthesis of the CK1 PROTAC degrader AH078.

CK1δ-IN-7 (Compound 488) is an inhibitor of casein kinase 1δ (CK1δ).

CK1δ-IN-10 (Compound 85) is an inhibitor of casein kinase 1 (CK1), specifically targeting CK1δ (CSNKID), with an IC50 value of 0.255 μM.

CK1δ-IN-5 (Compound 24) is an inhibitor of casein kinase 1δ (CK1δ) and can be used in the study of neurodegenerative diseases.

CK1δ-IN-9 (Compound 8) is an inhibitor of casein kinase 1 (CK1), specifically targeting CK1δ with an IC50 of 1.4 nM. The compound also inhibits p38α and p38β with IC50 values of 0.25 μM and 0.78 μM, respectively. CK1δ-IN-9 exhibits favorable pharmacokinetic properties, including high oral bioavailability (70%) and moderate clearance.

CK1δ-IN-8 (Compound 429) is a CK1δ inhibitor suitable for Alzheimer's disease research.

p38αMAPK/CK1δ inhibitor-1 (Compound 3) exhibits inhibitory activity against p38αMAPK and CK1δ, with IC50 values of 0.185 µM and 0.089 µM, respectively.

CK1δ-IN-1 (example 939) is an inhibitor of casein kinase 1δ (CK1δ). CK1δ-IN-1 is utilized for research in Alzheimer's disease.

CK1-IN-3 is casein kinase 1 (CK1) inhibitor and can be used for research on the treatment or prevention of diseases associated with circadiantiazol rhythm, inflammation diseases.

Epiblastin A is an inhibitor of Casein Kinase 1 (CK1). Epiblastin A engages CK1 isoenzymes in cell lysate and induces efficient conversion of epiblast stem cells (EpiSCs) into embryonic stem cells (cESCs).

CKI-7 is a potent, ATP-competitive inhibitor of casein kinase 1 (CK1; IC50: 6 μM; Ki: 8.5 μM) and a selective Cdc7 kinase inhibitor. It also inhibits SGK, ribosomal S6 kinase-1 (S6K1), and MSK1.

AMG-548 is a selective and orally active p38α MAPK inhibitor (Ki = 0.5 nM), with higher selectivity than p38β, p38γ, and p38δ, and can also inhibit the TNFα, CK1δ/ε, and Wnt signalling pathways.